Bodey G P, Elting L, Jones P, Alvarez M E, Rolston K, Fainstein V
Cancer. 1987 Jul 15;60(2):255-62. doi: 10.1002/1097-0142(19870715)60:2<255::aid-cncr2820600224>3.0.co;2-l.
Imipenem/cilastatin was administered during 153 febrile episodes occurring in cancer patients and the response rate was 68%. Considering only documented infections the response rate was 71%. Patients who received imipenem as initial therapy had a higher response rate than patients who received it after failing other antibiotics (77% versus 68%). The overall response rates for septicemias and pneumonias were 75% and 58%. Among the 57 gram-negative infections 77% responded, but the response rate was substantially higher if imipenem was used as initial therapy (94% versus 69%). The poorest response rate was observed when imipenem was given as secondary therapy for Pseudomonas infections (50%), but most of these patients had failed to respond to other appropriate antibiotics. The only serious side effect was seizures which occurred in ten patients, although eight of them had other predisposing factors. Imipenem appears to be a useful antibiotic for treatment of infections, even in neutropenic cancer patients.
亚胺培南/西司他丁应用于癌症患者发生的153次发热性发作期间，有效率为68%。仅考虑有记录的感染，有效率为71%。接受亚胺培南作为初始治疗的患者比在其他抗生素治疗失败后接受该药物的患者有更高的有效率（77%对68%）。败血症和肺炎的总体有效率分别为75%和58%。在57例革兰氏阴性菌感染中，77%有反应，但如果亚胺培南用作初始治疗，有效率显著更高（94%对69%）。当亚胺培南作为铜绿假单胞菌感染的二线治疗药物时，有效率最差（50%），但这些患者中的大多数对其他合适的抗生素无反应。唯一严重的副作用是癫痫发作，10例患者出现癫痫，尽管其中8例有其他诱发因素。亚胺培南似乎是一种治疗感染的有用抗生素，即使在中性粒细胞减少的癌症患者中也是如此。
